ArticleThe Journal of experimental medicine2005
Defective thrombus formation in mice lacking coagulation factor XII.
Article in The Journal of experimental medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 270 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
270 citing papers in PubMed, 671 citations in OpenAlex.
- Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.Frontiers in immunology · 2023Trial
- Development of an Interpretable QSAR Model for Predicting Coagulation Factor XIIa Inhibitors Using Ensemble Machine Learning.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.British journal of haematology · 2026Article
- Trypsin is as procoagulant as factor XIIa.Bleeding, thrombosis and vascular biology · 2026Article
- Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model.Blood vessels, thrombosis & hemostasis · 2026Article
- Factor XII in Thrombosis and Thromboinflammation: From Molecular Biology to Clinical Translation.International journal of molecular sciences · 2026Review
- Article
- Prognostic significance of coagulation factor activity in acute stroke: a retrospective cohort study.Frontiers in medicine · 2026Article
- Proteomics of arterial thrombi in acute limb ischemia.Journal of thrombosis and thrombolysis · 2025Article
- Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis.Nature communications · 2025Article
- Revisiting the Link Between Factor XII and Recurrent Pregnancy Loss: A Scoping Review.American journal of reproductive immunology (New York, N.Y. : 1989) · 2025Article
- A novel homozygous frameshift mutation (p.Lys365Glnfs*69) in a family with hereditary factor XII deficiency: a case report.Journal of hematopathology · 2025Article
- Factor XII-driven coagulation traps bacterial infections.The Journal of experimental medicine · 2025Article
- Coagulation Factor XII Is an Antibacterial Protein That Acts Against Bacterial Infection via Its Heavy Chain.International journal of molecular sciences · 2025Article
- Activation of the Coagulation Cascade as a Universal Danger Sign.Current issues in molecular biology · 2025Review
- Heparin Resistance in Patients Receiving Extracorporeal Membrane Oxygenation: A Review.Journal of clinical medicine · 2024Review
- Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors.Journal of thrombosis and thrombolysis · 2024Article
- Breaking boundaries: exploring recent advances in anticoagulation and thrombosis management: a comprehensive review.Annals of medicine and surgery (2012) · 2024Review
- Bat-derived oligopeptide LE6 inhibits the contact-kinin pathway and harbors anti-thromboinflammation and stroke potential.Zoological research · 2024Article
- A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation.Nature communications · 2024Article
210 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood coagulation is thought to be initiated by plasma protease factor VIIa in complex with the membrane protein tissue factor. In contrast, coagulation factor XII (FXII)-mediated fibrin formation is not believed to play an important role for coagulation in vivo. We used FXII-deficient mice to study the contributions of FXII to thrombus formation in vivo. Intravital fluorescence microscopy and blood flow measurements in three distinct arterial beds revealed a severe defect in the formation and stabilization of platelet-rich occlusive thrombi. Although FXII-deficient mice do not experience spontaneous or excessive injury-related bleeding, they are protected against collagen- and epinephrine-induced thromboembolism. Infusion of human FXII into FXII-null mice restored injury-induced thrombus formation. These unexpected findings change the long-standing concept that the FXII-induced intrinsic coagulation pathway is not important for clotting in vivo. The results establish FXII as essential for thrombus formation, and identify FXII as a novel target for antithrombotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.